Loading
Zymeworks Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by EcoR1 Capital, LLC, was filed 19 May 2025.
Zymeworks Inc.: what insiders have been doing
This page follows insider dealings at Zymeworks Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Vancouver, Canada. The group dates from 2003. The last twelve months, up to 23 October 2026, brought 25 filings signed by 7 insiders.
No insider bought on the market over the period, while 5 insiders filed 11 sales totalling €4.3M. Galbraith Kenneth filed the largest sale, €1.1M, on 22 December 2025.
Most trades are made public on the day they happen. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (3,167 companies, median 24 filings), a count of 25 filings is above the norm. Looking back to 2017, when coverage begins, insiders filed 54 purchases and 127 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 106.0 m USD and net income at -81.1 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
346
Thresholds
n/a
Buy Volume
€101M
54 ops. · all time
Sell Volume
€51M
127 ops. · all time
Who traded when
BuySaleEcoR1 Capital, LLC36 buys
Kenneth Galbraith6 sales
Paul Andrew Moore5 sales
Jeffrey T. L. Smith3 sales
Adam Schayowitz1 sale
Mark Hollywood1 sale
Since the insiders bought
- +99.8%Entry US$12.43 · Close at T+365 US$24.84
- -39.7%Entry US$14.39 · Close at T+365 US$8.67
- -16.3%Entry US$36.45 · Close at T+365 US$30.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Zymeworks Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$41.21.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,146 of 26,280 companies
14.6
score / 100
Value27
Quality3
FCF yld-1.7%
Earn yld-4.0%
EV/EBITDA·
ROE-72%
Gross mgn·
Net mgn-77%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$26.91
Analyst consensus
14 analystsStrong buy
US$32.00Target US$41.21(+53%)US$60.00
Income statement
RevenueUS$106M
EBITDA-US$81.4M-77% margin
Net income-US$81.1M-76.6% margin
Valuation
PER (forward)29.8x
P/Book23.9x
Beta1.17
Balance sheet & cash
Market capUS$1.9B
Total debtUS$18.3M
Free Cash Flow-US$35.4M
Debt / Equity20%
Profitability & ownership
ROE-72.3%
ROA-24.1%
% insiders1.3%
% institutions99.5%
Last declaration on 9 October 2026
Declarations346 total
13,832 shares@ US$25.260.018% mcap100.0% of flowCommon StockSEC144:0002127119-26-000004
37,037 shares0Common StockSEC:0002127119-26-000006:0
13,832 shares@ US$25.850.019% mcap100.0% of flowCommon StockSEC:0002127119-26-000006:1
939 shares@ US$22.220.0011% mcap100.0% of flowCommon StockSEC:0002104446-26-000009:0
6,120 shares@ US$22.6786.7% of flowCommon StockSEC:0001193125-26-011885:1
17,666 shares0Common StockSEC:0001193125-26-011885:0
30,424 shares@ US$22.6715.1% of flowCommon StockSEC:0001193125-26-010790:1
9,560 shares@ US$22.6718.3% of flowCommon StockSEC:0001193125-26-010834:1
9,310 shares@ US$22.6731.9% of flowCommon StockSEC:0001193125-26-010865:1
17,666 shares0Common StockSEC:0001193125-26-010865:0
17,666 shares0Common StockSEC:0001193125-26-010834:0
64,000 shares0Common StockSEC:0001193125-26-010790:0
459 shares@ US$10.55100.0% of flowCommon StockSEC:0001193125-26-006727:0
66,666 shares0Common StockSEC:0001193125-26-003097:2
20,000 shares0Common StockSEC:0001193125-26-003095:2
22,657 shares@ US$25.1012.4% of flowCommon StockSEC:0001193125-26-003097:1
31,686 shares@ US$25.1017.3% of flowCommon StockSEC:0001193125-26-003097:3
9,289 shares@ US$25.1019.5% of flowCommon StockSEC:0001193125-26-003095:1
10,821 shares@ US$25.1022.7% of flowCommon StockSEC:0001193125-26-003095:3
10,538 shares@ US$25.1039.8% of flowCommon StockSEC:0001193125-26-003102:1
47,668 shares0Common StockSEC:0001193125-26-003097:0
17,168 shares0Common StockSEC:0001193125-26-003095:0
20,000 shares0Common StockSEC:0001193125-26-003102:0
47,528 shares@ US$27.0228.0% of flowCommon StockSEC:0001193125-25-329028:1
100,000 shares0Common StockSEC:0001193125-25-329028:0
25 of 346 declarations
About Zymeworks Inc.
Zymeworks Inc. is a biotechnology company listed in the United States on the NASDAQ under the ticker ZYME. While the company is headquartered in Vancouver, British Columbia, its investor case is primarily framed by North American capital markets, U.S. regulation, and global partnering opportunities. For French-speaking investors in France, Belgium, and Switzerland, Zymeworks fits squarely within the healthcare/pharma segment, with valuation driven by clinical execution, regulatory milestones, and royalty-based economics rather than by traditional product sales alone. ([ir.zymeworks.com](https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-provides-corporate-update-and-reports-first-quarter-3?utm_source=openai))
Founded as a research-driven biotech platform company, Zymeworks has evolved from a pure R&D organization into a business model that combines internal drug development with monetization of licensed assets. The company emphasizes proprietary technologies for bispecific antibodies and antibody-drug conjugates (ADCs), aiming to create differentiated therapeutics for difficult-to-treat diseases. Its strategy reflects a blend of scientific innovation and asset aggregation, with a growing focus on future cash flows from partnered and licensed products. ([ir.zymeworks.com](https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-positive-topline-data-pivotal-herizon-btc-01/?utm_source=openai))
Read moreShow less
Operationally, Zymeworks is focused mainly on oncology, while also maintaining programs in inflammation and autoimmune disease. The most important asset in the current portfolio is Ziihera® (zanidatamab-hrii), a HER2-directed bispecific antibody developed under partnerships with companies such as Jazz Pharmaceuticals and BeOne. Ziihera received accelerated FDA approval in November 2024 for previously treated HER2-positive biliary tract cancer, and subsequent 2025–2026 clinical updates reported positive phase 3 data in gastroesophageal adenocarcinoma, strengthening the commercial and regulatory outlook. Zymeworks is also advancing wholly owned ADC candidates such as ZW191 and ZW251, which broaden the pipeline beyond its lead partnered asset. ([ir.zymeworks.com](https://ir.zymeworks.com/news-releases/news-release-details/fda-grants-us-approval-ziiherar-zanidatamab-hrii-treatment?utm_source=openai))
From a competitive standpoint, Zymeworks stands out through a two-engine model: first, it builds scientifically differentiated drug candidates; second, it seeks value through royalties, milestones, and future economics on licensed assets. That structure gives the company more strategic breadth than a single-asset biotech, but it still faces the usual sector risks, including clinical failure, regulatory delays, commercialization dependence on partners, and capital allocation pressure. In other words, the equity story is high-upside but remains inherently execution sensitive. ([ir.zymeworks.com](https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-strategic-initiative-optimize-value-licensed?utm_source=openai))
Recent milestones have been important. In early 2026, Zymeworks outlined a new strategic initiative to optimize the value of licensed products and entered into a royalty-backed financing agreement to strengthen liquidity and support strategic flexibility. Management also highlighted improved financial flexibility and continued investment in its ADC and multispecific antibody pipeline. Taken together, these developments indicate a company transitioning toward a more mature, asset-backed biotech profile while still preserving meaningful optionality from clinical development. ([ir.zymeworks.com](https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-and-royalty-pharma-enter-250-million-royalty-backed?utm_source=openai))
